Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Karyopharm Therapeutics (KPTI) Leases (2019 - 2025)

Karyopharm Therapeutics' Leases history spans 7 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Leases fell 22.71% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, down 22.71%, while the annual FY2025 figure was $4.5 million, 22.71% down from the prior year.
  • Leases reached $4.5 million in Q4 2025 per KPTI's latest filing, down from $4.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $9.0 million in Q1 2021 to a low of $2.6 million in Q3 2024.
  • Average Leases over 5 years is $5.8 million, with a median of $5.6 million recorded in 2023.
  • Peak YoY movement for Leases: plummeted 46.08% in 2024, then skyrocketed 80.97% in 2025.
  • A 5-year view of Leases shows it stood at $7.9 million in 2021, then dropped by 21.19% to $6.2 million in 2022, then crashed by 31.45% to $4.3 million in 2023, then surged by 37.61% to $5.9 million in 2024, then fell by 22.71% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Leases are $4.5 million (Q4 2025), $4.7 million (Q3 2025), and $5.1 million (Q2 2025).